Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5E73H)

Drug Name

Revusiran Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Amyloidosis	5D00	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Transthyretin messenger RNA (TTR mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Patisiran	DMWSA0V	Amyloidosis	5D00	Approved	[2]
Vutrisiran	DMM1Z9G	Hereditary amyloidosis	5D00.2	Approved	[3]
Eplontersen	DMON9CY	Amyloid polyneuropathy	5D00.20	Approved	[4]
ISIS-TTR	DM4U5NF	Amyloidosis	5D00	Phase 3	[5]
ALN-TTR01	DMCSEUY	Amyloidosis	5D00	Phase 1	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Transthyretin messenger RNA (TTR mRNA)	TTPOYU7	TTHY_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02319005) ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.
3	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals.
4	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217388
5	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
6	Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013 Aug 29;369(9):819-29.